<DOC>
	<DOCNO>NCT03061955</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy concurrent administration influenza vaccine patient receive anti-PD1 immunotherapy ( nivolumab pembrolizumab ) . This prospective observational study , aim assess patient tolerance treatment , adverse event ( incidence , grade , need hospitalization ) , incidence influenza infection , seroconversion rate .</brief_summary>
	<brief_title>Safety Efficacy Concurrent Administration Influenza Vaccine Patients Undergoing Anti-PD-1 Immunotherapy ( Nivolumab , Pembrolizumab )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>18 year older Currently receive immunotherapy antiPD1 agent ( Nivolumab Pembrolizumab ) Have receive influenza vaccination prior study entry date upcoming flu season 20162017 No previous contraindication receive influenza vaccination Histologically proven cancer Expected lifetime least 12 week Previous cancer Autoimmune disease immunosuppressive treatment Corticosteroid treatment Those potential indication change chemotherapy treatment 42 day follow start treatment History clinically virologically confirm influenza infection previous six month Previous contraindication receive influenza vaccination Previous allergic/adverse reaction influenza vaccination Have receive influenza vaccination prior study entry date upcoming 20162017 flu season Positive anti influenza antibody titer determine baseline blood determination ( day 0 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>